A 48-weeks national multicenter randomized open clinical trial evaluating tolerance and efficacy of a treatment simplification by lopinavir/ritonavir versus continuation of current treatment in HIV-infected patients with a viral load inferior to 50 copies/mL since 6 months at least

Trial Profile

A 48-weeks national multicenter randomized open clinical trial evaluating tolerance and efficacy of a treatment simplification by lopinavir/ritonavir versus continuation of current treatment in HIV-infected patients with a viral load inferior to 50 copies/mL since 6 months at least

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Antiretrovirals; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms KALESOLO
  • Most Recent Events

    • 26 Jul 2017 Results (n=637) of pooled analysis of NCT00140751, NCT00421551, NCT00946595 trials analysing distribution of ultrasensitive viral load (USVL) and impact of USVL on virological failure presented at the 9th International AIDS Society Conference on HIV Science
    • 10 Jun 2017 Biomarkers information updated
    • 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top